Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to Its Board of Directors
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to Its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Mar. 12, 2024-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors. Dr. Nathan is Medical Director of Inova's Advanced Lung Disease Program and Lung Transplant Program and a Professor at the University of Virginia. Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.
聖地亞哥--(美國商業資訊)--2024年3月12日-- Gossamer Bio, Inc. 納斯達克股票代碼：GOSS）是一家臨床階段的生物製藥公司，專注於開發和商業化用於治療肺動脈高壓（PAH）和與間質性肺病（PH-ILD）相關的肺動脈高壓（PH-ILD）的肺動脈高壓，今天宣佈任命醫學博士史蒂芬·內森和斯凱·德雷南爲董事會成員。內森博士是Inova晚期肺病項目和肺移植項目的醫學總監，也是弗吉尼亞大學的教授。斯凱·德雷南是House of Skye有限公司的創始人、首席執行官兼創意總監，曾任資本集團合夥人兼高級生物製藥分析師。
Dr. Nathan brings to the Board a wealth of medical expertise, particularly in PH-ILD, which occurs when pulmonary hypertension occurs in association with interstitial lung disease, a broad array of conditions manifesting as scarring of the lungs. With only one approved therapeutic option in the US, and none in the EU, PH-ILD represents an indication of high unmet need. With Dr. Nathan's guidance, Gossamer is poised to expand its clinical program for seralutinib to include PH-ILD, underscoring Gossamer's commitment to addressing rare forms of pulmonary hypertension, or PH.
Nathan博士爲董事會帶來了豐富的醫學專業知識，特別是在PH-ILD方面，PH-ILD發生在肺動脈高壓與間質性肺病有關時，間質性肺病是一種表現爲肺部疤痕的各種疾病。由於美國只有一種批准的治療選擇，而在歐盟卻沒有，PH-ILD表明需求未得到滿足。在Nathan博士的指導下，Gossamer準備擴大其賽拉替尼的臨床計劃，將PH-ILD包括在內，這凸顯了Gossamer對治療罕見肺動脈高壓（PH）的承諾。
Ms. Drynan joins the Board with an extensive background in finance, investment, and entrepreneurship, specializing in the biotechnology industry. Her more than 25 years of experience in investing and advising public biotechnology companies and technology companies, in addition to navigating the complexities of the financial markets, will be invaluable as Gossamer continues to advance the development of seralutinib and position itself as a leader in the treatment of PH.
Drynan 女士加入董事會時擁有豐富的金融、投資和創業背景，專攻生物技術行業。隨着Gossamer繼續推進seralutinib的開發並將自己定位爲PH治療的領導者，她在投資和諮詢上市生物技術公司和科技公司方面擁有超過25年的經驗，除了駕馭金融市場的複雜性外，將是無價的。
"The addition of Dr. Nathan to our Board signifies a pivotal moment in Gossamer's evolution," said Faheem Hasnain, Co-Founder, Chairman and CEO of Gossamer Bio. "It not only demonstrates our dedication to the PH community, but it also solidifies our standing in the field, as we broaden our focus beyond PAH.
Gossamer Bio聯合創始人、董事長兼首席執行官Faheem Hasnain表示：“內森博士加入我們的董事會標誌着Gossamer演變的關鍵時刻。“這不僅表明了我們對公共衛生界的奉獻精神，而且還鞏固了我們在該領域的地位，因爲我們將重點擴大到PAH以外。
"Ms. Drynan's expertise will strengthen our ability to capitalize on opportunities and navigate the financial landscape. Her proven track record as a biotech analyst and her entrepreneurial drive undoubtedly enhance our decision-making. Together these appointments elevate our strategic vision and position Gossamer for continued success."
“Drynan女士的專業知識將增強我們抓住機遇和駕馭金融格局的能力。她作爲生物技術分析師的良好記錄和創業精神無疑增強了我們的決策。這些任命共同提升了我們的戰略願景，爲Gossamer的持續成功奠定了基礎。”
Dr. Nathan is the Medical Director of Inova's Advanced Lung Disease Program and Lung Transplant Program, a position he has held since 1996. He is also a Professor of Medical Education at the University of Virginia, a position he has held since 2020.
內森博士是 Inova 晚期肺部疾病項目和肺移植項目的醫學總監，他自 1996 年以來一直擔任該職務。他還是弗吉尼亞大學的醫學教育教授，自2020年以來一直擔任該職位。
Dr. Nathan is board certified in pulmonary diseases, critical care medicine and internal medicine. As the author of more than 500 publications, Dr. Nathan is internationally recognized for his expertise in advanced lung diseases. He is co-editor of two books on idiopathic pulmonary fibrosis, or IPF, that provide pulmonologists and other healthcare workers with an up-to-date review of the background and advances in the field: Idiopathic Pulmonary Fibrosis and Guide to Clinical Management of Idiopathic Pulmonary Fibrosis. Dr. Nathan is a reviewer for multiple journals and is on the editorial board for the journal, Thorax. He has served on multiple committees, including FDA advisory boards, as well as steering committees for clinical trials in IPF and PH.
Nathan 博士獲得了肺部疾病、重症監護醫學和內科領域的董事會認證。作爲 500 多篇出版物的作者，內森博士因其在晚期肺部疾病方面的專業知識而享譽國際。他是兩本關於特發性肺纖維化（IPF）的書的共同編輯，這兩本書爲肺科醫生和其他醫護人員提供了該領域的背景和進展的最新回顧： 特發性肺纖維化 和 特發性肺纖維化臨床管理指南。內森博士是多份期刊的審稿人，也是該期刊的編輯委員會成員， 胸部。他曾在多個委員會任職，包括FDA顧問委員會以及IPF和PH臨床試驗指導委員會。
Dr. Nathan is a member of several professional medical associations, including the American Thoracic Society, the American College of Chest Physicians, and the International Society for Heart and Lung Transplantation. Dr. Nathan received an M.B.B.cH. from the University of Witwatersrand Medical School.
內森博士是多個專業醫學協會的成員，包括美國胸科學會、美國胸科醫師學會和國際心肺移植學會。內森博士擁有威特沃特斯蘭德大學醫學院的工商管理碩士學位。
Ms. Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., which she founded in 2016. House of Skye is a modern fashion house and a commerce, content, and technology company, which has secured several patents covering artificial intelligence, technology, and design utility. She has secured significant investment and strategic partnerships for her new companies including a multi-level partnership with Accelerate360 and serves as a trusted advisor to tech and data companies including Nuda Foods, Vibely, VMD Ventures, and MNTN. Her entrepreneurial and creative achievements have been featured in Forbes, Bloomberg, Harper's Bazaar, Glamour, and Elle, amongst other global media publications.
Drynan 女士是 House of Skye, Ltd. 的創始人、首席執行官兼創意總監，該公司於 2016 年創立。House of Skye是一家現代時裝屋，也是一家商業、內容和技術公司，已獲得多項專利，涵蓋人工智能、技術和設計實用程序。她已經爲自己的新公司獲得了重要的投資和戰略合作伙伴關係，包括與Accelerate360的多層次合作伙伴關係，並且是Nuda Foods、Vibely、VMD Ventures和MNTN等科技和數據公司的值得信賴的顧問。她的創業和創造成就曾在《福布斯》、《彭博社》、《Harper's Bazaar》、《Glamour》和《Elle》等全球媒體出版物中發表過。
From 2008 to 2020, Ms. Drynan was a Partner and a Senior BioPharma Analyst for Capital Group, where she became one of the largest investors in biopharma, globally. Her vision and insights were critical to contributing to Capital Group's more than $2 trillion in assets by leading a variety of biopharma investing syndicates in private offerings, IPOs and secondary offerings. Prior to joining Capital Group, she served as a Portfolio Manager and Global Head of Healthcare managing more than $1 billion in assets for Credit Suisse Asset Management. Ms. Drynan also held senior executive roles and was an investment professional, specializing in healthcare, at Lord Abbett, New Vernon Associates, and Putnam Investments. Ms. Drynan received a B.A. in Latin American Studies and Spanish from Wellesley College and served as a Research Assistant at the Whitehead Institute for Biomedical Research at MIT.
從2008年到2020年，Drynan女士是資本集團的合夥人兼高級生物製藥分析師，成爲全球最大的生物製藥投資者之一。她的願景和見解對於通過領導各種生物製藥投資集團進行私募發行、首次公開募股和二次發行，爲資本集團超過2萬億美元的資產做出貢獻至關重要。在加入資本集團之前，她曾擔任投資組合經理兼全球醫療保健主管，管理瑞士信貸資產管理超過10億美元的資產。Drynan女士還曾在Lord Abbett、新弗農協會和普特南投資公司擔任高級管理職務，是一名投資專業人士，專攻醫療保健。Drynan 女士擁有韋爾斯利學院拉丁美洲研究和西班牙語學士學位，並曾在麻省理工學院懷特黑德生物醫學研究所擔任研究助理。
About Gossamer Bio
關於 Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension.
Gossamer Bio是一家臨床階段的生物製藥公司，專注於治療肺動脈高壓的seralutinib的開發和商業化。其目標是成爲肺動脈高壓領域的行業領導者，改善肺動脈高壓患者的生活。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312927389/en/
For Investors and Media:
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com
對於投資者和媒體：
布萊恩·吉羅多，首席運營官兼首席財務官
Gossamer Bio 投資者關係
ir@gossamerbio.com
Source: Gossamer Bio, Inc.
來源：Gossamer Bio, Inc.
譯文內容由第三人軟體翻譯。